Dr. Michaelson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Cox 640 Hematology Oncology
Boston, MA 02114Phone+1 617-726-5187Fax+1 617-724-3166
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2002
- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
- Albert Einstein College of MedicineClass of 1997
Certifications & Licensure
- MA State Medical License 1999 - 2026
- NH State Medical License 2021 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2005 Jul 26
- Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2007 Dec 01
- Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma Start of enrollment: 2009 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 425 citationsKidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J. Motzer, Eric Jonasch, Neeraj Agarwal, Sam B. Bhayani, William P Bro
Journal of the National Comprehensive Cancer Network. 2017-06-01 - 499 citationsCabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN ...Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson
Journal of Clinical Oncology. 2017-02-20 - 1248 citationsActivity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic ...Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding
Journal of Clinical Oncology. 2006-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: